Strategic Collaboration DDI sits within OSUCCC – James, enabling access to oncology clinical development resources and a network of industry-adjacent partners, presenting a door for pharma/biotech collaborations, sponsored research, and early-stage drug development partnerships.

Small Team, Big Impact With a lean 2-10 employee footprint, DDI offers agility and tight project focus, making it an attractive co-development or sponsored research partner for nimble teams seeking rapid decision cycles and clear value delivery in oncology programs.

University Access Leveraging Ohio State University’s research assets, preclinical and early development capabilities, and an advisory board of seasoned industry experts, DDI provides a pathway for de-risked early assets to attract venture funding and move toward clinical milestones.

Funding Range Reported revenue in the $1M–$10M band, indicating early-stage commercialization potential and opportunities to align with mid- to late-stage collaboration deals, milestone-based and license arrangements with larger partners.

Tech Stack & Compliance Utilizes standard industry tools (MATLAB, SAS, Jenkins, ServiceNow, Palo Alto Firewalls) suggesting readiness for data-intensive drug development and secure collaboration environments, which can appeal to partners prioritizing reproducibility, data governance, and compliant workflows.